Skip to Content

The pandemic has pushed South Korea’s Celltrion to further expand beyond its core business of making “biosimilars,” or cheaper generic versions of name-brand “biologic” drugs and treatments. In October, the U.S. Food and Drug Administration granted emergency use authorization for Celltrion’s rapid COVID-19 testing kit, Sampinute, which promises to deliver results within 10 minutes and with a 94% sensitivity rate. The company is also developing a COVID-19 antibody treatment, to reduce the severity of the coronavirus once patients are infected, and has received South Korean regulatory approval to begin Phase III clinical trials of the drug.

Courtesy of Celltrion
Lists ranking Celltrion
Future 50 - 2020Explore this year's ranking of the 50 companies wi...READ MOREview in list